Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 4289 - 4296 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCN2176 | Dronedarone |
|
Dronedarone is a derivative of amiodarone which is classified as a Class III antiarrhythmic agent. It shows rate-dependent inhibition of the rapid Na+ current, inhibits α and β-adrenergic receptors like Class II agents, exhibits blockade of K+ outward currents as the main mechanism of action of Class III, and effectively block slow Ca2+ inward currents (Class IV).
|
|
| BCN2177 | Dasatinib monohydrate |
|
1. Dasatinib monohydrate is a selective protein tyrosine kinase inhibitor with immunomodulatory properties that abrogates multiple signal transduction pathways in immune cells, it may be used to treat multiple sclerosis.
2. Dasatinib is a 2-aminothiazole-derived inhibitor of Src family kinases, inhibits c-Abl and Bcr-Abl tyrosine kinase activity and shows efficacy against imatinib-resistant Bcr-Abl mutations. 3. Combined treatment with bortezomib plus Dasatinib monohydrate caused cell cycle arrest in the G1 phase through inactivation of PDGFRβ and promoted bortezomib-induced apoptosis in GIST-T1 cells. 4. Dasatinib monohydrate monotherapy demonstrates anti‑ovarian cancer activities. The effects of Dasatinib monohydrate and paclitaxel treatments on ovarian cancer cells appeared to be mediated by the Src pathway. |
|
| BCN2178 | Tenofovir disoproxil |
|
1. Tenofovir disoproxil fumarate monotherapy is superior to continuous add-on therapy in patients with LAM-resistant CHB with a suboptimal response to LAM plus ADV.
2. Tenofovir disoproxil has anti-HIV-1 activity. |
|
| BCN2179 | Pemetrexed disodium |
|
1. Pemetrexed disodium activates MEK/ERK-dependent cyto-protective autophagy, and inhibition of this pathway potentiates Pemetrexed disodium's activity in HepG2 cells.
2. Pemetrexed disodium is a multitargeted antifolate cytotoxic agent mainly used in lung cancer, is an antimetabolite drug, that inhibits enzymes involved in nucleotides bio-synthesis arresting cancer cells cycle. |
|
| BCN2180 | Ezetimibe |
|
1. Ezetimibe is known as a Niemann-Pick C1-Like 1 (NPC1L1) inhibitor and has been used as an agent for hypercholesterolemia, Ezetimibe and simvastatin are equipotent in lowering lipid levels in hypercholesterolemic patients with coexisting PCOS.
2. Ezetimibe administration can improve glycemic control and increase glucagon like peptide-1 (GLP-1), an incretin hormone with anti-diabetic properties, a possible novel biological role of Ezetimibe in glycemic control to stimulate intestinal GLP-1 secretion via the MEK/ERK signaling pathway. |
|
| BCN2181 | Pramipexole dihydrochloride |
|
1. Pramipexole dihydrochloride could be used to treat Parkinson disease.
|
|
| BCN2182 | Roflumilast |
|
1. Roflumilast is a phosphodiesterase 4 inhibitor that may improve lung function and reduce the frequency of exacerbations in patients with COPD.
2. Suppression of hematological and immunological markers of inflammation and enhanced apoptosis in animals treated with Roflumilast points to the possibility of a beneficial effect of Roflumilast in allergic inflammation. 3. Roflumilast has anti-inflammatory and immunomodulatory potential,it will be useful in the treatment of chronic inflammatory disorders such as asthma and chronic obstructive pulmonary disease. |
|
| BCN2183 | Ramelteon |
|
1. Ramelteon significantly improves symptoms in patients with gastroesophageal reflux disease and significantly improves patients' sleep experience.
2. Ramelteon could be a potential therapeutic drug, in adjunctive treatment of learning and memory deficits seen in patients with schizophrenia. 3. Ramelteon is effective for the prevention of delirium, ramelteon administered nightly to elderly patients admitted for acute care may provide protection against delirium. 4. Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment, demonstrates no significant effects indicative of potential for abuse or motor and cognitive impairment at up to 20 times the recommended therapeutic dose. |
|